CN1809370A - B7－h3作为免疫调节剂的应用 - Google Patents

B7－h3作为免疫调节剂的应用 Download PDF

Info

Publication number
CN1809370A
CN1809370A CNA2004800170492A CN200480017049A CN1809370A CN 1809370 A CN1809370 A CN 1809370A CN A2004800170492 A CNA2004800170492 A CN A2004800170492A CN 200480017049 A CN200480017049 A CN 200480017049A CN 1809370 A CN1809370 A CN 1809370A
Authority
CN
China
Prior art keywords
val
leu
ala
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA2004800170492A
Other languages
English (en)
Chinese (zh)
Inventor
V·凌
B·M·卡雷诺
M·科林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1809370A publication Critical patent/CN1809370A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800170492A 2003-04-17 2004-04-16 B7－h3作为免疫调节剂的应用 Withdrawn CN1809370A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46334203P 2003-04-17 2003-04-17
US60/463,342 2003-04-17

Publications (1)

Publication Number Publication Date
CN1809370A true CN1809370A (zh) 2006-07-26

Family

ID=33310770

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800170492A Withdrawn CN1809370A (zh) 2003-04-17 2004-04-16 B7－h3作为免疫调节剂的应用

Country Status (14)

Country Link
US (1) US20050002935A1 (https=)
EP (1) EP1620119A2 (https=)
JP (2) JP2006523711A (https=)
KR (1) KR20060017496A (https=)
CN (1) CN1809370A (https=)
AU (1) AU2004231748A1 (https=)
BR (1) BRPI0409476A (https=)
CA (1) CA2521847A1 (https=)
CO (1) CO5700783A2 (https=)
MX (1) MXPA05011050A (https=)
NO (1) NO20054790L (https=)
RU (1) RU2005135739A (https=)
WO (1) WO2004093894A2 (https=)
ZA (1) ZA200508367B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
WO2020132789A1 (zh) * 2018-12-24 2020-07-02 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用
CN111454357A (zh) * 2019-08-14 2020-07-28 上海岺樾生物医药科技有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN112239502A (zh) * 2019-07-18 2021-01-19 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113144181A (zh) * 2021-04-20 2021-07-23 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
WO2024148521A1 (zh) * 2023-01-10 2024-07-18 周田弘 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用
US12312406B2 (en) 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2412377A1 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412377A1 (en) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US6891030B2 (en) * 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
WO2003014293A2 (en) * 2001-08-02 2003-02-20 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN103687945B (zh) * 2011-04-25 2016-10-12 第一三共株式会社 抗-b7-h3抗体
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN109937212B (zh) * 2017-03-31 2022-06-21 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
US12312406B2 (en) 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
CN113260703A (zh) * 2018-12-24 2021-08-13 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用
WO2020132789A1 (zh) * 2018-12-24 2020-07-02 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用
US12415846B2 (en) 2018-12-24 2025-09-16 Shanghai Renyousheng Gene Technology Co., Ltd. Recombinant human 2IG-B7-H3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof
CN112239502A (zh) * 2019-07-18 2021-01-19 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN112239502B (zh) * 2019-07-18 2024-07-30 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111454357A (zh) * 2019-08-14 2020-07-28 上海岺樾生物医药科技有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN113144181A (zh) * 2021-04-20 2021-07-23 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
WO2024148521A1 (zh) * 2023-01-10 2024-07-18 周田弘 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用

Also Published As

Publication number Publication date
MXPA05011050A (es) 2006-03-17
RU2005135739A (ru) 2006-03-20
CO5700783A2 (es) 2006-11-30
NO20054790D0 (no) 2005-10-18
WO2004093894A8 (en) 2005-05-19
NO20054790L (no) 2005-11-16
JP2006523711A (ja) 2006-10-19
WO2004093894A2 (en) 2004-11-04
CA2521847A1 (en) 2004-11-04
BRPI0409476A (pt) 2006-05-02
ZA200508367B (en) 2007-04-25
WO2004093894A3 (en) 2005-03-24
EP1620119A2 (en) 2006-02-01
KR20060017496A (ko) 2006-02-23
AU2004231748A1 (en) 2004-11-04
JP2007191489A (ja) 2007-08-02
US20050002935A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
CN1809370A (zh) B7－h3作为免疫调节剂的应用
CN1181201C (zh) Lag-3剪接变体
CN1218961C (zh) 破骨细胞形成抑制因子、其核苷酸序列和制备方法
CN1263507C (zh) April受体(bcma)及其用途
CN1217956C (zh) 可溶性单链t细胞受体蛋白
CN1309734C (zh) 与免疫应答有关的新颖多肽
CN1555272A (zh) 调节免疫应答的组合物和方法
CN1902227A (zh) Tim－3配体及其方法
CN1516739A (zh) 利用hmg片段作为抗炎症试剂
CN1256147C (zh) Cd8作为细胞免疫系统的抑制剂
CN1531545A (zh) 降低融合蛋白的免疫原性
CN1774445A (zh) 用于治疗rage相关病症的组合物和方法
CN1359302A (zh) 治疗免疫性疾病的药用组合物
CN1942206A (zh) 治疗免疫性疾病的药物组合物
CN101048509A (zh) 用于产生蛋白质的体系和方法
CN1133049A (zh) 黑素瘤抑制蛋白质
CN1784424A (zh) 编码人癌胚抗原的合成基因及其用途
CN101065401A (zh) 骨保护素变异蛋白
CN1620466A (zh) 胱氨酸结折迭蛋白质
CN1145589A (zh) 通过T细胞α链的抗原特异性的免疫调节方法
CN1170931C (zh) 血管发生相关分子
CN1195374A (zh) 整合素调节/信号传递的细胞质调节剂
CN1795205A (zh) Spex组合物和使用方法
CN1901932A (zh) 细胞因子拮抗剂分子
CN101039956A (zh) 细胞表面糖蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication